Paul H Plotz

US Patent:

8536148, Sep 17, 2013

Filed:

Sep 2, 2010

Appl. No.:

13/391265

Inventors:

Nina N. Raben - N. Bethesda MD, US
Cynthia Schreiner - Gowanda NY, US
Rebecca Baum - Highland UT, US
Shoichi Takikita - Rockville MD, US
Tao Xie - Rockville MD, US
Paul H. Plotz - Washington DC, US

Assignee:

The United States of America, as Represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

A61K 48/00

US Classification:

514 44, 536 245, 536 2431, 536 241

Abstract:

Provided herein are methods of treating lysosomal storage disease, for instance Pompe disease, through inhibition of autophagy. Optionally, treatment is administered as an adjunct to enzyme replacement therapy (ERT).

US Patent:

20040203096, Oct 14, 2004

Filed:

May 14, 2004

Appl. No.:

10/474163

Inventors:

Nina Raben - Rockville MD, US
Nina Lu - Rockville MD, US
Bo Yan - Rockville MD, US
Paul Plotz - Washington DC, US
Yesenia Rivera - Bethesda MD, US

International Classification:

C12N009/36
C07H021/04

US Classification:

435/069100, 435/320100, 435/325000, 435/206000, 536/023200

Abstract:

The invention provides recombinant native lysosomal enzymes produced by liver cells, preferably in vitro, and methods of using the native recombinant lysosomal enzymes to treat enzyme deficiencies in vivo. Lysosomal enzymes, including acid alpha-glucosidase (GAA), produced by liver cells apparently undergo the post-translational modifications necessary to achieve good enzymatic activity. The resulting enzymes can be taken up by various other cells and can correct phenotypic abnormalities of distant organs with enzyme deficiencies. In certain preferred embodiments, the enzyme is GAA and the methods are especially adapted for treatment of type II glycogen storage disease in mammals, including humans.

US Patent:

20130331309, Dec 12, 2013

Filed:

Aug 19, 2013

Appl. No.:

13/970265

Inventors:

- , unknown
Tao Xie - Rockville MD, US
Cynthia Schreiner - Gowanda NY, US
Rebecca Baum - Highland UT, US
Shoichi Takikita - Rockville MD, US
Paul Plotz - Washington DC, US

International Classification:

C12N 15/113

US Classification:

514 11, 514 44 A

Abstract:

Provided herein are methods of treating lysosomal storage disease, for instance Pompe disease, through inhibition of autophagy. Optionally, treatment is administered as an adjunct to enzyme replacement therapy (ERT).

US Patent:

56630662, Sep 2, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/479156

Inventors:

Nina Raben - Rockville MD
Ralph Nichols - Columbia MD
Paul Plotz - Washington DC
Richard Leff - Charleston SC

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC
National Institutes of Health - Bethesda MD

International Classification:

C12N 900
C12N 500
C12P 2106
C07K 100

US Classification:

435183

Abstract:

Recombinant Histidyl tRNA synthetase produced by non-mammalian host cells is used in a sensitive assay to determine the presence of autoimmune diseases in mammals. Methods for isolating, cloning and expressing rHRS are described. In addition, a kit for determining the presence of an autoimmune disease is provided.

US Patent:

54847036, Jan 16, 1996

Filed:

Apr 22, 1993

Appl. No.:

8/052404

Inventors:

Nina Raben - Rockville MD
Ralph Nichols - Columbia MD
Paul Plotz - Washington DC
Richard Leff - Charleston SC

Assignee:

United States of America - Washington DC

International Classification:

G01N 33564

US Classification:

435 74

Abstract:

Recombinant Histidyl tRNA synthetase produced by non-mammalian host cells is used in a sensitive assay to determine the presence of autoimmune diseases in mammals. Methods for isolating, cloning and expressing rHRS are described. In addition, a kit for determining the presence of an autoimmune disease is provided.